The down-regulation of NAT10 results in the reduction of ac4C modification in specific regions of mRNA, impairing translational efficiency of BCL9L, SOX4, AKT1 as well as the stability of BCL9R and SOX5, thereby reducing bladder cancer burden [24]. This evidence concerns the gene NAT10 and urinary bladder carcinoma.